Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
126.1 USD | -2.63% | -3.59% | +15.64% |
02:30pm | Merck: positive results for Keytruda in breast cancer | CF |
01:48pm | Merck Says Phase 3 Trial of Keytruda in Triple Negative Breast Cancer Met Overall Survival Endpoint | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.64% | 328B | |
+38.25% | 727B | |
-7.22% | 354B | |
+0.30% | 277B | |
+13.36% | 243B | |
+7.22% | 205B | |
-6.50% | 203B | |
+4.28% | 164B | |
-1.96% | 164B | |
-1.31% | 122B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04